Trade
Natco Pharma share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹983.55(2.30%)July 10, 2026 15:48:00 PM IST
- NSE
- BSE
- Vol : 736.39 K (NSE + BSE)Last 20 day avg : 834.72 K
Natco Pharma is trading 2.30% upper at Rs 983.55 as compared to its last closing price. Natco Pharma has been trading in the price range of 987.95 & 947.95. Natco Pharma has given 6.48% in this year & 2.90% in the last 5 days. Natco Pharma has TTM P/E ratio 12.30 as compared to the sector P/E of 26.80.There are 9 analysts who have initiated coverage on Natco Pharma. There are 2 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 267.90 Crores in its last quarter.Listed peers of Natco Pharma include Torrent Pharmaceuticals (-0.03%), Divi's Laboratories (0.31%), Cipla (-0.20%).The Mutual Fund holding in Natco Pharma was at 1.92% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Natco Pharma was at 16.99% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 12, 2026, 12:31 PM UTC
- BetaLow volatility0.70Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.08The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.52Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation0.46The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Natco Pharma News
Natco Pharma Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | 4,895.20 | -0.03 | 1,65,669.16 | 67.32 | 17.1 | 0.83 | 17.62 |
| Divi's Laboratories | 6,832.30 | 0.31 | 1,81,268.32 | 78.61 | 11.52 | 0.46 | 0.01 |
| Cipla | 1,438.75 | -0.20 | 1,16,228.74 | 22.95 | 3.87 | 0.87 | 0.81 |
| Dr Reddy's Laboratories | 1,245.50 | -1.91 | 1,03,714.06 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | 1,935.25 | -0.19 | 4,64,320.36 | 36.24 | 5.77 | 0.92 | 0.50 |
Mutual Fund Ownership
View allNatco Pharma Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-29 | Audited Results |
| 2026-03-24 | Scheme of Arrangement |
| 2026-02-12 | Quarterly Results & Interim Dividend |
| 2025-11-14 | Quarterly Results & Interim Dividend |
| 2025-08-12 | Quarterly Results & Interim Dividend |
About the company Natco Pharma
- IndustryBiotechnology & Drugs
- ISININE987B01026
- BSE Code524816
- NSE CodeNATCOPHARM
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with a focus on research and development. It develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Its segments include Pharmaceuticals and Agro chemicals. The Pharmaceuticals segment is engaged in the manufacturing and selling of bulk drugs, finished dosage formulations. The Agro Chemicals segment focuses on the manufacturing and selling of agro chemicals. It is also engaged in developing, manufacturing and marketing finished dosage formulations (FDF), active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio consists of two categories of agrochemicals - pesticides and bioproducts. The key focus area is to fill the gaps in the portfolio through crop phenology analysis. It has manufacturing facilities in India which cater to both domestic and international markets.
Natco Pharma Share Price FAQs
Natco Pharma is trading at 983.55 as on Fri Jul 10 2026 10:18:00. This is 2.30% upper as compared to its previous closing price of 961.45.
The market capitalization of Natco Pharma is 17616.35 Cr as on Fri Jul 10 2026 10:18:00.
The average broker rating on Natco Pharma is Hold. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 3 analysts have given a hold rating
- 2 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Natco Pharma is 1226.10 whereas the 52 wk low is 789.30
Natco Pharma can be analyzed on the following key metrics -
- TTM P/E: 12.30
- Sector P/E: 26.80
- Dividend Yield: 0.52%
- D/E ratio: 0.08
Natco Pharma reported a net profit of 1418.50 Cr in 2026.
The Mutual Fund Shareholding was 1.92% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Natco Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.